Mounjaro and Statins: Can You Take Tirzepatide with Cholesterol Medication?

If you take a statin for high cholesterol and are considering Mounjaro (tirzepatide) for weight loss, the first question is usually a practical one: can I take both at the same time? It is a sensible concern. Statins are among the most widely prescribed medicines in the UK, with around eight million adults taking one daily, and adding any new drug raises legitimate questions about safety and interactions.

At CutKilo, our doctors see this combination regularly. Many patients referred for supervised weight loss already take atorvastatin, rosuvastatin or simvastatin for cardiovascular risk reduction. Here is what the clinical evidence actually says about using Mounjaro alongside cholesterol medication, and why, for most people, the two medicines work better together than either does alone.

Yes, you can take Mounjaro and a statin together. There is no known pharmacokinetic interaction between tirzepatide and HMG-CoA reductase inhibitors (statins). The SURMOUNT and SURPASS clinical trials enrolled thousands of participants who were already taking statins, and no additional safety signals emerged from the combination. Your prescribing doctor may, however, need to review your statin dose over time because Mounjaro itself improves cholesterol levels, which can change the risk-benefit calculation for continued lipid-lowering therapy.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It slows gastric emptying, which is part of how it reduces appetite and controls blood sugar. Slower stomach emptying can, in theory, alter how quickly other oral medicines are absorbed into the bloodstream. Patients and pharmacists sometimes worry that a statin taken by mouth could be affected by this mechanism.

The concern is understandable but largely theoretical for statins. Eli Lilly’s pharmacokinetic studies tested tirzepatide alongside commonly co-prescribed oral drugs. While a small delay in peak absorption was observed for some medicines (notably oral contraceptives containing ethinylestradiol), the total amount of drug absorbed, measured by area under the curve, remained clinically unchanged for statins. The MHRA Summary of Product Characteristics for Mounjaro does not list any statin as a contraindication or a clinically significant interaction.

It is also worth noting that GLP-1 receptor agonists have been prescribed alongside statins for over a decade. Liraglutide (Saxenda) and semaglutide (Wegovy, Ozempic) share the same delayed-gastric-emptying effect, and years of real-world prescribing data have shown no meaningful interaction with statins in either class.

Across the SURMOUNT programme (the pivotal weight-loss trials for tirzepatide), a substantial proportion of participants were taking statins at baseline. In SURMOUNT-1, approximately 17% of the 2,539 enrollees used lipid-lowering therapy. In SURMOUNT-2, which focused on adults with type 2 diabetes and obesity, that figure was considerably higher, reflecting the strong overlap between diabetes, obesity and dyslipidaemia.

No trial arm reported an increased rate of statin-related adverse events such as myalgia (muscle pain), rhabdomyolysis or liver enzyme elevation in patients taking both drugs. The safety profile of tirzepatide was consistent regardless of whether participants were on background statin therapy.

In the SURPASS trials (type 2 diabetes focus), the same pattern held. Statin co-administration did not alter the efficacy or tolerability of tirzepatide, and no dose adjustment was required. The FDA and MHRA approval documents for Mounjaro both confirm that no clinically relevant drug interaction exists between tirzepatide and statins.

One of the lesser-known benefits of tirzepatide is its independent effect on lipid metabolism. Weight loss alone improves cholesterol, but tirzepatide appears to offer lipid benefits beyond what weight reduction would predict. In SURMOUNT-1, participants on the 15 mg dose saw mean reductions of approximately 7% in LDL cholesterol, 25% in triglycerides and a 5% increase in HDL cholesterol over 72 weeks. Triglyceride reductions were particularly striking, likely driven by improved insulin sensitivity and reduced hepatic lipogenesis.

For a detailed look at these lipid changes and what they mean for cardiovascular risk, see our guide on Mounjaro and cholesterol.

These improvements mean that some patients who were previously at the threshold for statin therapy may no longer meet NICE prescribing criteria after sustained weight loss on Mounjaro. Others may be able to reduce their statin dose. Neither change should be made without consulting your GP or cardiologist, but it is a conversation worth initiating at your next medication review, particularly if your QRISK3 score has improved alongside your weight.

Atorvastatin is the most commonly prescribed statin in the UK. It has a long half-life (approximately 14 hours for the active metabolite), can be taken at any time of day and is metabolised by the CYP3A4 enzyme in the liver. Tirzepatide does not inhibit or induce CYP3A4, so there is no pharmacokinetic basis for an interaction. No dose adjustment is needed.

Rosuvastatin is the most potent statin by milligram. It is not primarily metabolised by cytochrome P450 enzymes, which makes it even less susceptible to drug interactions in general. No interaction with tirzepatide has been observed or is expected based on its pharmacology.

Simvastatin has a shorter half-life and is conventionally taken in the evening to align with the body peak cholesterol synthesis overnight. It is metabolised by CYP3A4, but since tirzepatide does not affect this enzyme, the combination is safe. The slight delay in gastric emptying does not reduce overall simvastatin absorption.

Pravastatin and fluvastatin are less commonly prescribed but follow the same principle. Neither has a known interaction with GLP-1 receptor agonists, and no special precautions apply when combining them with Mounjaro.

Because tirzepatide slows gastric emptying, some clinicians recommend spacing oral medicines apart from the injection by a few hours. In practice, this matters more for time-sensitive drugs like oral contraceptives than for statins, which are taken once daily and have a long duration of action.

Most statins (atorvastatin, rosuvastatin) can be taken at any time of day and are not meaningfully affected by gastric transit speed. Simvastatin is conventionally taken in the evening because of its short half-life, but even here, the slight delay caused by tirzepatide does not reduce overall drug absorption to a clinically relevant degree.

Our standard advice at CutKilo is to continue taking your statin at whatever time your GP originally recommended. There is no clinical need to move it to a different time because you have started Mounjaro.

Although the combination is safe for most people, there are situations where your doctor should review both prescriptions together:

• You develop unexplained muscle pain, tenderness or weakness. These are potential statin side effects that warrant review regardless of whether you take Mounjaro.
• Your blood glucose drops more than expected, especially if you also take insulin or a sulfonylurea alongside both drugs. For more on this, read our article about hypoglycaemia on tirzepatide.
• Your latest lipid panel shows a significant improvement in LDL, triglycerides or HDL, which may mean your statin dose can be reduced or your cardiovascular risk reassessed.
• You are starting or stopping any other medicine that interacts with your statin, for example certain macrolide antibiotics, azole antifungals or grapefruit juice in large quantities.

At CutKilo, we request a baseline lipid panel before starting treatment and repeat it at three and six months. This allows us to track your cholesterol response alongside your weight loss and flag any changes that need attention from your GP or cardiologist.

Mounjaro and statins can be taken together safely. There is no pharmacokinetic interaction between tirzepatide and any commonly prescribed statin, whether atorvastatin, rosuvastatin, simvastatin or others. The clinical trials that led to Mounjaro approval included statin users and found no additional risks from the combination. In fact, because tirzepatide independently improves LDL cholesterol, triglycerides and HDL, the two medicines often complement each other in reducing overall cardiovascular risk. The most important thing is to keep your prescribing team informed so that your statin dose can be adjusted if your lipid profile improves significantly during treatment.

Can I take atorvastatin and Mounjaro at the same time of day? Yes. Atorvastatin can be taken at any time and is not meaningfully affected by tirzepatide effect on gastric emptying. There is no need to space the two apart.

Will Mounjaro replace my statin? Not automatically. While tirzepatide improves cholesterol, a statin targets LDL through a different mechanism (inhibiting HMG-CoA reductase in the liver). Whether you can reduce or stop your statin depends on your overall cardiovascular risk profile, not just your LDL number. Always discuss changes with your GP or cardiologist.

Does Mounjaro make statin side effects worse? There is no evidence that tirzepatide increases the risk of statin-related muscle pain, liver enzyme changes or any other known statin adverse effect. If you experience new muscle symptoms, report them to your doctor regardless of which other medicines you take.

I take rosuvastatin. Is that safe with Mounjaro? Yes. Rosuvastatin has no known interaction with tirzepatide. It is not primarily metabolised by cytochrome P450 enzymes, making it even less susceptible to drug interactions. Continue taking it as prescribed.

Should I get my cholesterol tested more often while on Mounjaro? It is good practice to recheck your lipid panel three to six months after starting tirzepatide. This helps your doctor decide whether your statin dose is still appropriate given the lipid improvements Mounjaro may bring.